Pharmacogenetic Data With Clinical Outcomes Should Be Described In Label
Executive Summary
Pharmacogenetic variations with demonstrated clinical outcomes should be discussed in drug labeling, members of FDA's Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science said at its April 23 meeting
You may also be interested in...
FDA Pharmacogenomics Advisory Committee Will Oversee Data Submissions
FDA is forming a pharmacogenomics advisory committee to handle voluntary genomic data submissions, Office of Clinical Pharmacology & Biopharmaceutics Director Lawrence Lesko, PhD, said
Strattera QTc Concerns Addressed During Review; Lilly Avoids Warning
Lilly's Strattera review provides one example of a successful effort by a sponsor to address potential safety issues for a pending application without agreeing to a risk management program
Pharmacogenetic Test Should Be Added To 6-MP Label, FDA Cmte. Says
GlaxoSmithKline's Purinethol (mercaptopurine) should include labeling recommending use of pharmacogenetic testing to guide dosing, the Clinical Pharmacology Subcommittee of FDA's Pharmaceutical Science Advisory Committee concluded at its Oct. 23 meeting